InicioTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Cierre anterior
3,85 $
Intervalo diario
3,60 $ - 3,95 $
Intervalo anual
3,03 $ - 14,80 $
Cap. bursátil
3,42 M USD
Volumen medio
22,31 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Ingresos | — | — |
Gastos operativos | 666,00 mil | -53,88 % |
Ingresos netos | -790,00 mil | 59,90 % |
Margen de beneficio neto | — | — |
Beneficios por acción | — | — |
EBITDA | -666,00 mil | 65,46 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 2,83 M | -58,12 % |
Activos totales | 2,92 M | -63,85 % |
Responsabilidades totales | 483,00 mil | -66,55 % |
Patrimonio total | 2,44 M | — |
Acciones en circulación | 914,23 mil | — |
Precio-valor contable | 1,44 | — |
Rentabilidad económica | -51,03 % | — |
Retorno sobre capital | — | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -790,00 mil | 59,90 % |
Efectivo de operaciones | -506,00 mil | 77,47 % |
Efectivo de inversión | — | — |
Efectivo de financiación | -62,00 mil | -115,27 % |
Variación neta del flujo de caja | -568,00 mil | 57,49 % |
Flujo de caja libre | -193,25 mil | 80,89 % |
Información sobre la empresa
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Fundación
1991
Sitio web
Empleados
4
